What ligandrol dose do the sources report?

Strengths, forms and reported use
Internet productLabel claim per unitFound per unit
Capsules (90)4 mg1-5 mg3
Capsules (90)5 mg1-10 mg3
Tablets (30)15 mg5-20 mg3
Capsules (90)6 mg1-10 mg3
Solution (30 mL)10 mg/mL0.1-1 mg/mL3
Capsules (90)5 mgNo active agents detected3

In a 2013 phase I trial by Basaria and colleagues, 76 healthy men aged 21 to 50 were given placebo or 0.1, 0.3 or 1.0 mg of LGD-4033 daily by mouth for 21 days, and a phase II registry record (NCT02578095) for VK5211 lists four arms, placebo, 0.5 mg, 1.0 mg and 2.0 mg, each as once-daily (QD) capsules for 12 weeks in 108 adults aged 65 or older recovering from hip fracture.12

Strengths, forms and reported use

The table is set at the top of the page

A 2017 JAMA analysis by Van Wagoner and colleagues found that only 23 of 44 internet SARM products (52%) contained a SARM. It lists the 4, 5, 6 and 15 mg LGD-4033 capsules and tablets under "Identity and Dosage Match", a 30-mL solution labelled 10 mg/mL of LGD-4033 under "Identity Match but Dosage Does not Match", and a 5 mg LGD-4033 capsule under "No Active Agents Detected in Product".3 A search of DailyMed for "ligandrol" and "LGD-4033" found no label. The FDA says SARMs are not FDA approved, and a warning letter names a product sold as "LGD-4033 Ligandrol" as an unapproved new drug.45

A case report gives VK5211, the name in the registry record, as another name for LGD-4033.6 Two case reports describe use outside trials: a 32-year-old man, whose severe liver injury the authors attribute to Ligandrol, reported taking 1 mL (10 mg) daily for about 2 weeks, and a 25-year-old man took LGD-4033 10 mg with MK-677 15 mg daily for 5 weeks.67 The authors of the first report say that dose is 10 to 100 times higher than the doses given in the trial.6

Doses and schedule in the trials

In the 2013 phase I trial, Basaria and colleagues gave each dose of LGD-4033 or placebo daily by mouth with 8 ounces of water after an overnight fast, 20 doses over 21 days with no dose on day 2.1 They chose 0.1, 0.3 and 1.0 mg because an earlier single-dose study had established safety up to 22 mg.1 LGD-4033 had a half-life of 24 to 36 hours there, which the authors say suits once daily or less frequent dosing.1

TrialDose and schedulePeopleLength
Basaria 2013, phase IPlacebo, 0.1, 0.3 or 1.0 mg daily by mouth176 healthy men aged 21 to 50 randomized, 68 completed21 days (20 doses), then 5 weeks of observation
VK5211, NCT02578095, phase IIPlacebo, 0.5 mg, 1.0 mg and 2.0 mg, each as once-daily (QD) capsules2108 adults aged 65 or older recovering from hip fracture (28, 29, 26 and 25 per arm)12 weeks

Both trials gave each group a fixed dose, and a search of the Basaria trial text and the registry record found no stepping or titration of one person's dose. The Basaria authors call for longer randomized trials.1

Frequently asked questions

How is ligandrol mixed or dissolved?

A search of DailyMed, PubMed and the papers cited here found no mixing or dissolving instruction for ligandrol, and no label or maker leaflet for a powder. A doping-control study added a 1 mg/mL ethanol stock of LGD-4033 to 120 mL of drinking yoghurt to give five healthy male volunteers single doses of 1, 10 or 50 µg, and the same doses on five consecutive days.8

How should ligandrol be stored?

A search of DailyMed, PubMed and the papers cited here found no label, maker leaflet or stability data for ligandrol, before or after mixing.

What does the FDA say about SARMs sold online?

The FDA says SARMs are often marketed as dietary supplements or sold for research use only, but are considered unapproved drugs.4 It lists liver injury and acute liver failure among the health problems linked to SARMs.4

References

  1. PubMed Central (full text, article page). The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men. 2013. pmc.ncbi.nlm.nih.gov
  2. ClinicalTrials.gov (US National Library of Medicine). NCT02578095: Acute Hip Fracture Study in Patients 65 Years or Greater. 2025. clinicaltrials.gov
  3. PubMed Central (full text, article page). Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. 2017. pmc.ncbi.nlm.nih.gov
  4. FDA. Social Media Posts by Influencers and Online Sellers Promote SARMs Use. 2025. fda.gov
  5. FDA. Dynamic Health Group dba SARMS AMERICA - 719257 - 12/12/2025. 2025. fda.gov
  6. ACG Case Reports Journal (full text, PubMed Central). Ligandrol (LGD-4033)-Induced Liver Injury. 2020. pmc.ncbi.nlm.nih.gov
  7. Experimental physiology (PubMed abstract). LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. 2022. pubmed.ncbi.nlm.nih.gov
  8. Analytical and Bioanalytical Chemistry (full text, PubMed Central). Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes. 2022. pmc.ncbi.nlm.nih.gov